Clinical outcomes in an adult patient with mannose phosphate isomerase-congenital disorder of glycosylation who discontinued mannose therapy

Loading...
Thumbnail Image

Authors

Naoman, Kinza
Hendriksz, Christian J.
Radcliffe, Graham
Roncaroli, Federico
Moreea, Sulleman
Hussain, Afifah
Stepien, Karolina M.

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier

Abstract

The mannose phosphate isomerase-congenital disorder of glycosylation (MPI-CDG) is caused by phosphomannose isomerase deficiency. Clinical features include hyperinsulinaemic hypoglycaemia, protein losing enteropathy, hepatomegaly and hepatic fibrosis, digestive symptoms and coagulation abnormalities. The condition is treated with mannose supplementation. Long-term outcomes in adults are not well described. We present a case of an adult female patient who discontinued mannose therapy in her adolescence. In adulthood she developed gastrointestinal problems, chronic anaemia and osteophytes in her knees.

Description

Keywords

Adult, Clinical outcomes, Mannose phosphate isomerase-congenital disorder of glycosylation (MPI-CDG), Phosphomannose isomerase deficiency, Coagulation abnormalities, Digestive symptoms, Hyperinsulinaemic hypoglycaemia, Protein losing enteropathy, Hepatomegaly, Hepatic fibrosis

Sustainable Development Goals

Citation

Noman, K., Hendriksz, C.J., Radcliffe, G. et al. 2020, 'Clinical outcomes in an adult patient with mannose phosphate isomerase-congenital disorder of glycosylation who discontinued mannose therapy', Molecular Genetics and Metabolism Reports, vol. 25, pp. 1-4.